Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
JAMA · 13.01.2026 · 335 (2) · 129
DOI: 10.1001/jama.2025.20620 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 13.01.2026. Verfasst von Christie M Ballantyne und 11 weiteren Autor:innen. Beteiligte Einrichtung: Texas Heart Institute, Baylor College of Medicine, Houston, Texas. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Hyperlipoproteinemia Type II, PCSK9 Inhibitors. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C). Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.
Objective
To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C levels despite use of statin therapy. Design, Setting, and Participants This phase 3, randomized clinical trial included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease. The trial was conducted at 59 sites across 17 countries; the first participant was screened on August 8, 2023, and the last follow-up visit occurred on April 7, 2025.
Interventions
Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks. Main Outcomes and Measures The primary outcome was the mean percentage change in LDL-C level at week 24. The secondary outcomes included the mean percentage change in LDL-C level at week 52, the mean percentage change at week 24 in levels of non–high-density lipoprotein cholesterol (non–HDL-C) and apolipoprotein B, and the median percentage change at week 24 in lipoprotein(a).
Results
Of the 303 participants (mean age, 52.4 [SD, 13.5] years; 51% were female) randomized, 293 (96.7%) completed the trial. The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline, all had statin current use (81.5% were taking a high-intensity statin), and 64.4% were taking ezetimibe. The mean percentage change in LDL-C level at week 24 was −58.2% in the enlicitide group vs 2.6% in the placebo group (between-group difference, −59.4% [95% CI, −65.6% to −53.2%]; P < .001). The mean percentage change in LDL-C level at week 52 was −55.3% in the enlicitide group vs 8.7% in the placebo group (between-group difference, −61.5% [95% CI, −69.4% to −53.7%]; P < .001). At week 24, the mean percentage change in non–HDL-C level was −52.3% in the enlicitide group vs 2.1% in the placebo group (between-group difference, −53.0% [95% CI, −58.5% to −47.4%]; P < .001), the mean percentage change in apolipoprotein B level was −48.2% vs 1.8%, respectively (between-group difference, −49.1% [95% CI, −54.0% to −44.3%]; P < .001), and the median percentage change in lipoprotein(a) level was −24.7% vs −1.6% (between-group difference, −27.5% [95% CI, −34.3% to −20.6%]; P < .001). The incidence of adverse events, serious adverse events, and study discontinuation due to adverse events was similar between groups.
Conclusions
Among adults with HeFH, treatment with enlicitide was well tolerated and significantly reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a). Trial Registration ClinicalTrials.gov Identifier: NCT05952869
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Texas Heart Institute, Baylor College of Medicine, Houston, Texas.
- Merck & Co, Inc, Rahway, New Jersey.
- Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
- Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
- Lipid Clinic, Oslo University Hospital, Oslo, Norway.
- NZ Clinical Research, Christchurch, New Zealand.
Zitieren
APA
Ballantyne, C. M., Gellis, L., Tardif, J. C., Banka, P., Navar, A. M., Asprusten, E. A., Scott, R., Stroes, E. S. G., Froman, S., Mendizabal, G., Wang, F., & Catapano, A. L. (2026). Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia. JAMA, 335(2), 129. https://doi.org/10.1001/jama.2025.20620
Vancouver
Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia. JAMA. 2026;335(2):129. doi:10.1001/jama.2025.20620
BibTeX
@article{Ballantyne2026,
author = {Ballantyne, Christie M and Gellis, Laura and Tardif, Jean-Claude and Banka, Puja and Navar, Ann Marie and Asprusten, Emil Andreas and Scott, Russell and Stroes, Erik S G and Froman, Samar and Mendizabal, Geraldine and Wang, Fan and Catapano, Alberico L},
title = {Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia},
journal = {JAMA},
year = {2026},
volume = {335},
number = {2},
pages = {129},
doi = {10.1001/jama.2025.20620}
}
EUVIMED